Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomic-guided isoniazid dose adjustment to shorten sputum conversion time in pulmonary tuberculosis
ChiCTR2500103612Phase 4Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of isoniazid in pulmonary tuberculosis (TB) (2 arms), sponsored by Beijing Chest Hospital. Primary endpoints: Time to sputum bacteria conversion to negative and NAT2 genotype. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
isoniazid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR2500103612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103612.